JLE

European Journal of Dermatology

MENU

Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia Volume 31, issue 1, January-February 2021

Figures


  • Figure 1
Authors
1 Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan
2 Department of Diagnostic Pathology, Asahikawa Medical University, Asahikawa, Japan

Dasatinib is an oral tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL). The development of TKIs, including imatinib, dasatinib, nilotinib, and ponatinib, has markedly improved the prognosis of patients with CML [1]. However, TKIs are associated with various cutaneous adverse reactions, including maculopapular rash, xerosis, alopecia, and keratosis pilaris [2]. Herein, we report a case [...]